| 81.61 1.66 (2.08%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 98.98 | 1-year : | 115.61 |
| Resists | First : | 84.75 | Second : | 98.98 |
| Pivot price | 79.15 |
|||
| Supports | First : | 75.95 | Second : | 70.51 |
| MAs | MA(5) : | 81.1 |
MA(20) : | 77.83 |
| MA(100) : | 74.17  |
MA(250) : | 66.74 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 73.1 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 89.38 | Low : | 39.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NUVL ] has closed below upper band by 30.9%. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 83.2 - 83.61 | 83.61 - 84.03 |
| Low: | 80.27 - 80.69 | 80.69 - 81.12 |
| Close: | 80.93 - 81.6 | 81.6 - 82.28 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Jul 2024
Nuvalent, Inc. (NASDAQ:NUVL) Stake Boosted by Sei Investments Co. - Defense World
Thu, 25 Jul 2024
Analysts Set Nuvalent, Inc. (NASDAQ:NUVL) PT at $96.33 - MarketBeat
Thu, 25 Jul 2024
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Wed, 24 Jul 2024
Seven Eight Capital LP Takes $1.17 Million Position in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Tue, 23 Jul 2024
Nuvalent (NASDAQ:NUVL) Receives “Outperform” Rating from Wedbush - Defense World
Tue, 23 Jul 2024
ProShare Advisors LLC Boosts Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 108.8 (%) |
| Shares Short | 7,230 (K) |
| Shares Short P.Month | 6,720 (K) |
| EPS | -2.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.4 % |
| Return on Equity (ttm) | -26.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -33.73 |
| PEG Ratio | 0 |
| Price to Book value | 7.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -43.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|